OnKure Therapeutics, Inc. (Nasdaq: OKUR) (“OnKure”), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, announces the completion of its previously announced merger of OnKure, Inc. and Reneo Pharmaceuticals, Inc. (“Reneo”). The combined company will operate under the name OnKure Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Global Market on October 7, 2024 under the ticker symbol “OKUR”. Concurrent with the closing of the merger, the company completed a $65 million private placement with a group of new and existing investors.
Read the full article: OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65M //
Source: https://www.globenewswire.com/news-release/2024/10/04/2958522/0/en/OnKure-Announces-Closing-of-Merger-with-Reneo-Pharmaceuticals-and-Concurrent-Private-Placement-of-65-Million.html